Adenovirus Infection, Cytomegalovirus Infection
Conditions
Keywords
viral infections post HSCT, virus-specific T-cells
Brief summary
Invasive infections with CMV and Adenovirus, not responding to virostatic treatment are treated with virusspecific donor derived or autologous virusspecific T-cells.
Detailed description
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only treatment option for several haematological diseases. In spite of substantial progress in this field, viral infections, mainly cytomegalovirus (CMV) and adenovirus (HAdV) in the context of delayed immunoreconstitution remain life threatening complications. Weekly screening of high-risk patients and preemptive virostatic treatment has become a current strategy. Unfortunately, treatment with virostatic drugs is associated with substantial nephro- and myelo-toxicity and of limited effectiveness. Human adenovirus (HAdV) and cytomegalvirus (CMV) disseminated infections are associated with mortality rates of up to 50%-60% despite virostatic treatment. All HSCT patients at the St. Anna Children's Hospital undergo weekly viral quantitative PCR-screening for HAdV and CMV and weekly PB FACS (Fluorescence Activated Cell Sorter)-Analysis according to the local HSCT-diagnostic SOP (Standard Operating Procedure) from day -7 until day +100 Patients with HAdV or CMV viremia will receive preemptive treatment with either gancyclovir (in case of isolated CMV-viremia) or Cidofovir (in case of HAdV viremia or combined HAdV/CMV infection). In case of increasing viremia ≥ 1log despite antiviral treatment for two weeks or stable with 10E6 viral load and the absence of virus specific T-cells in the recipient, the treating physician will check, if the patient is eligible for seVirus-T-cell infusion (see inclusion criteria). Study Design: Mononuclear Donor-Cells from peripheral blood (100 ml extra donation) will be cryopreserved at the time-point of HSCT. In case of progredient viremia these cells will be stimulated with interleukin-15 and peptides out of the virus molecule, virusspecific T-Cells are enriched for 2-3 logs-teps and potentially alloreactive cells diluted at the same time. This new approach reduces the risk of graft-versus-host-disease (GvHD) and enables the infusion of virus-specific T-cells also from haploidentical donors.
Interventions
BIOLOGICALvirus-specific T-Cells
infusion
Sponsors
St. Anna Kinderkrebsforschung
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No
Inclusion criteria
* Age at timepoint of HSCT ≤18 years undergoing allogeneic stem cell transplantation * Presence of HAdV or CMV-specific T-cells in the donor or CMV-specific T-cells in the recipient pre-transplant * Stable (≥ 10E6) or increasing viremia despite antiviral treatment post HSCT * Absence of HAdV or CMV -specific T cells post HSCT * Karnofsky / Lansky score \>50% * Pregnancy excluded * Informed study participation consent is signed
Exclusion criteria
* Infusion of polyclonal or monoclonal T-cell directed antibodies within 28 days before seVirus T-Cell infusion * Multiple organ failure at screening-timepoint seVirus T-Cell infusion * History of GvHD Gr III-IV or actual GvHD Gr III-IV * Pregnancy * Treatment with granulocyte transfusion within the last 72 hours * Karnofsky / Lansky score \<50% * Subject is unwilling or unable to comply with the study procedures * High dose treatment with steroids (≥ 2mg/kg/d, methylprednisone-equivalent)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Non pre-existing Immune System Disorders i.e. Allergic reaction, Anaphylaxis, Cytokine release syndrome or Serum sickness of Grade III-IV of seVirus-T-cell infusion within 48 hours from infusion | 48 hours | assessment is performed according to CTCAE 4.3 Scale |
| De novo acute GvHD > Gr II or increase of pre-existing GvHD more than 1 grade from 2 weeks post infusion until 8 weeks post infusion | 8 weeks | assessment is performed according to Glucksberg Scale, modified for paediatic patients from D. Jacobsohn (publication Blood 2008) |
| Incidence of graft rejection | 8 weeks | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Detection of virus-specific T-cells within 8 weeks after T-cell therapy. Measurement of the viral load following the infusion of seVirus-T-cells | 6 months | — |
| Correlation of the presence of virus-specific T-cells with partial reduction (>1 log viral copies /ml blood) or complete clearance of viral load | 8 weeks | — |
| Tracking of the infused T-cells by NGS (Next Generation Sequencing) of the TCRs (T-Cell Receptors)-beta rearrangements | 3 months | PBMCs (isolated from about 10ml of peripheral blood) will be resuspended in TRIzol, a ready to use mixture important for later DNA isolation. The samples will undergo DNA isolation using a multiplex TCR-beta PCR approach in combination with NGS of the generated amplicons and detailed bioinformatic interpretation of the generated sequence data. Current high-throughput sequencing technologies such as Illumina, (HiSeq) enable the analysis of T-cell receptor repertoires in an unprecedented depth. As every T-cell harbours a unique TCR-beta rearrangement, we will be able to track T-cell expansion even on a single cell level. |
Countries
Austria
Outcome results
None listed